XORTX Therapeutics Inc
XRTX0.625USD
-0.014-2.13%
Handelsschluss 11/04, 16:00（ET）Kurse um 15 Minuten verzögert
2.37MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über XORTX Therapeutics Inc Unternehmen
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.
XORTX Therapeutics Inc Informationen
BörsenkürzelXRTX
Name des UnternehmensXORTX Therapeutics Inc
IPO-datumSep 30, 2015
CEODr. Allen W. Davidoff, Ph.D.
Anzahl der mitarbeiter2
WertpapierartOrdinary Share
GeschäftsjahresendeSep 30
Addresse3710 - 33rd Street NW
StadtCALGARY
BörseTSX Venture Exchange (former Canadian Ventures Exchange)
LandCanada
PostleitzahlT2L 2M1
Telefon14034557727
Websitehttps://www.xortx.com/
BörsenkürzelXRTX
IPO-datumSep 30, 2015
CEODr. Allen W. Davidoff, Ph.D.
Führungskräfte von XORTX Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. James Neville (Jim) Fairbairn, CPA
Mr. James Neville (Jim) Fairbairn, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Ms. Abigail Jenkins
Ms. Abigail Jenkins
Independent Director
Independent Director
--
--
Mr. Stacy Evans, M.D.
Mr. Stacy Evans, M.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. James Neville (Jim) Fairbairn, CPA
Mr. James Neville (Jim) Fairbairn, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Thu, Oct 30
Aktualisiert: Thu, Oct 30
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Lincoln Alternative Strategies LLC
10.98%
Davidoff, Allen Warren
2.31%
Citadel Advisors LLC
0.74%
UBS Financial Services, Inc.
0.40%
Giovinazzo (Anthony)
0.18%
Andere
85.38%
Aktionäre
Aktionäre
Anteil
Lincoln Alternative Strategies LLC
10.98%
Davidoff, Allen Warren
2.31%
Citadel Advisors LLC
0.74%
UBS Financial Services, Inc.
0.40%
Giovinazzo (Anthony)
0.18%
Andere
85.38%
Aktionärstypen
Aktionäre
Anteil
Corporation
10.98%
Individual Investor
2.50%
Hedge Fund
0.74%
Investment Advisor
0.40%
Bank and Trust
0.08%
Andere
85.30%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
15
63.97K
1.23%
-645.66K
2025Q2
17
129.44K
3.30%
-739.58K
2025Q1
20
127.29K
3.49%
-606.22K
2024Q4
21
385.20K
10.34%
-244.07K
2024Q3
22
287.39K
12.35%
-145.77K
2024Q2
20
276.67K
12.12%
-141.93K
2024Q1
21
272.84K
13.24%
-121.02K
2023Q4
19
553.49K
27.69%
+481.09K
2023Q3
20
176.53K
8.83%
-185.14K
2023Q2
19
179.60K
8.98%
-178.94K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Davidoff, Allen Warren
120.45K
2.31%
+8.19K
+7.30%
Jul 22, 2025
Citadel Advisors LLC
38.47K
0.74%
+38.47K
--
Jun 30, 2025
UBS Financial Services, Inc.
20.79K
0.4%
+20.79K
--
Jun 30, 2025
Giovinazzo (Anthony)
9.63K
0.18%
--
--
Apr 30, 2025
National Bank of Canada
3.93K
0.08%
+3.76K
+2160.92%
Jun 30, 2025
Raymond James & Associates, Inc.
500.00
0.01%
+500.00
--
Jun 30, 2025
Van Damme (Paul Joseph)
7.11K
0.14%
--
--
Apr 30, 2025
Clearstead Advisors LLC
277.00
0.01%
--
--
Jun 30, 2025
Spartan Fund Management Inc.
--
0%
-119.30K
-100.00%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Datum
Art
Verhältnis
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
